StarTribune
Markets
Minnesota Stocks
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Avrobio Inc. Common Stock (NQ: AVRO)
15.30 USD  +0.62 (+4.22%)
Official Closing Price  /  Updated: 5:48 PM EST, Feb 15, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 161,000
Open 14.80
Bid (Size) 12.00 (1)
Ask (Size) 40.00 (4)
Prev. Close 14.68
Today's Range 14.22 - 15.51
52wk Range 11.85 - 53.70
Shares Outstanding 23,149,645
Dividend Yield N/A
Performance
YTD
-2.24%
-2.24%
1 Month
+14.52%
+14.52%
3 Month
-36.51%
-36.51%
6 Month
-60.43%
-60.43%
1 Year
-50.96%
-50.96%
Top News
More News
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday,... Read More
from GlobeNewswire News Releases
AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
AVROBIO, Inc. announces updated clinical data from ongoing Phase 1 and Phase 2 studies for AVR-RD-01 gene therapy for Fabry disease. Read More
from Business Wire News Releases
More News
Read More
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
from GlobeNewswire News Releases
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
from GlobeNewswire News Releases
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
from GlobeNewswire News Releases
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
from GlobeNewswire News Releases
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease
from GlobeNewswire News Releases
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
Implied IWN Analyst Target Price: $135
category ETFs
from ETF Channel
Oversold Conditions For AVROBIO (AVRO)
category Stocks
from Market News Video
A Peek Into The Markets: US Stock Futures Surge; All Eyes On Fed Decision
category WGO , A Peek Into The Markets , Pre/Market Outlook , and 15 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 

© 2019 StarTribune. All rights reserved.